Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial .
BIOPHYTIS SAFebruary 17, 2021 GMT
Clinical centers in France and Belgium will begin recruitment for Part 2 of the COVA Study following authorization from Regulatory Authorities
These approvals follow the previous authorizations obtained from Brazil and the United States in most clinical centers
Interim Analysis of Part 1 is expected in Q1 2021
Results from the full study (Part 1 and Part 2) are expected in Q2 2021
ADVERTISEMENT
PARIS and CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) Biophytis SA (NasdaqGS: BPTS; Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, includ
Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) Following Regulatory Authorities Approvals in France and Belgium - read this article along with other careers information, tips and advice on BioSpace
Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) Following Regulatory Authorities Approvals in France and Belgium
February 17, 2021 02:00 ET | Source: BIOPHYTIS SA BIOPHYTIS SA Romainville, FRANCE
Clinical centers in France and Belgium will begin recruitment for Part 2 of the COVA Study following authorization from Regulatory Authorities
These approvals follow the previous authorizations obtained from Brazil and the United States in most clinical centers
Interim Analysis of Part 1 is expected in Q1 2021
Results from the full study (Part 1 and Part 2) are expected in Q2 2021
PARIS and CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) Biophytis SA (NasdaqGS: BPTS; Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving f
Biophytis Announces the Start of Patient Recruitment in Brazil and the USA for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”)
Patient recruitment in Part 2 of the COVA Study will begin in most clinical centers in Brazil and the United States
Interim Analysis of Part 1 is expected in Q1 2021
Results from the full study (Part 1 and Part 2) are expected in Q2 2021
/EIN News/ PARIS and CAMBRIDGE, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces that patient recruitment at most clinical centers in Brazil and the United States will begin for Part 2 of its COVA Study assessing Sarconeos (BIO101) as a potential treatment for acute res
Published: Feb 03, 2021
Patient recruitment in Part 2 of the COVA Study will begin in most clinical centers in Brazil and the United States
Interim Analysis of Part 1 is expected in Q1 2021
Results from the full study (Part 1 and Part 2) are expected in Q2 2021
PARIS and CAMBRIDGE, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE)
Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces that patient recruitment at most clinical centers in Brazil and the United States will begin for Part 2 of its COVA Study assessing Sarconeos (BIO101) as a potential treatment for acute respiratory failure associated with COVID-19.